Disease Biology

0:39
Genomic advances in MM disease biology
Irene Ghobrial
0:54
Immune-mediated mechanisms of progression in MGUS and smouldering myeloma
Irene Ghobrial
19:31
Utilizing MRD for AML in the clinical setting
Jorge Sierra et al.
11:42
AML treatment: what does the data say?
Adriano Venditti et al.
9:08
Biological mechanisms of AML: a 2019 update
Klaus Metzeler et al.
15:02
The evolving landscape of ALL therapy and the impact of MRD
Dieter Hoelzer et al.
1:59
Understanding the biology behind AML relapse
Charles Craddock
5:41
Infectious complications of CLL: prevention and treatment
Ben Kennedy
2:36
Enhancer landscape in CLL upon BTK inhibition
Efterpi Kostareli
1:13
APL-2: mechanism of action within the complement system
Bruno Fattizzo
2:06
Defining the role of NFIC in AML
Namrata Rastogi
1:27
CyTOF flow cytometry in determining daratumumab response in myeloma
Francesca Gay
1:05
Ultrastratification of multiple myeloma via biomarkers
Francesca Gay
1:22
Immunomodulation and the microbiota
Christian Chabannon
1:27
Progress in AML & research at the University of Düsseldorf
Thomas Schröder
2:15
Transcription factor alterations in AML and risk: RUNX, CEPBA & EVI1
Ruud Delwel
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals